By [Your News Agency/Journalist Name]
The landscape of oncology is shifting from a physician-led hierarchy to a collaborative ecosystem where the patient’s voice is not just heard, but prioritized. At the forefront of this movement is METAvivor, a non-profit organization dedicated to the specific needs of the metastatic breast cancer (MBC) community. This month, Dr. Kelly Shanahan, President of METAvivor and a retired OB/GYN living with Stage IV breast cancer, provided a comprehensive update on the organization’s recent activities, personal health milestones, and the broader implications for MBC research and support.
Through a series of high-level exchanges in San Francisco and a milestone conference in Philadelphia, the METAvivor leadership has underscored a critical message: advocacy is the bridge between scientific innovation and the lived experience of the patient.
Main Facts: A Whirlwind of Advocacy and Recognition
The recent weeks have been a period of intense activity for the METAvivor board, characterized by two major industry and community events. Dr. Kelly Shanahan represented the organization at Genentech’s "Insight Exchange" and "Experience Exchange" in San Francisco. These forums brought together representatives from over 125 organizations, covering a vast spectrum of diseases, to discuss the future of oncology and patient-centric care.
Following the West Coast engagement, the focus shifted to the East Coast for the 20th Living Beyond Breast Cancer (LBBC) MBC Conference in Philadelphia. This event served as a nexus for the metastatic community, blending clinical updates with emotional support.
Key highlights from these engagements include:
- National Recognition: Dr. Kelly Shanahan and fellow board member Janice Cowden were honored as "Changemakers" by Living Beyond Breast Cancer for their tireless work in the MBC space.
- Board Mobilization: Eight METAvivor board members, along with Executive Director Crystal Moore, gathered in person—a rare occurrence for a team that typically operates via digital platforms—to foster community and manage organizational outreach.
- Clinical Success: In a significant personal update that mirrors the hope of the broader community, Dr. Shanahan reported that her current clinical trial is showing positive results, with imaging confirming decreased activity across her metastases after only two months of treatment.
Chronology: From Industry Insights to Community Connection
Phase I: The San Francisco Exchanges (Early Month)
The month began with Dr. Shanahan attending Genentech’s dual-exchange programs. The "Insight Exchange" focused specifically on the oncology pipeline, allowing advocates to provide feedback on drug development and trial design. This was followed by the "Experience Exchange," a massive cross-disease summit.
The presence of 125 different organizations highlights a growing trend in the pharmaceutical industry: the realization that the challenges faced by a patient with a rare genetic disorder often mirror those of a patient with metastatic cancer. These sessions focused on navigating the healthcare system, improving access to therapies, and ensuring that the "patient journey" is more than just a marketing term.
Phase II: The 20th LBBC MBC Conference (Mid-Month)
The transition to Philadelphia marked a shift from the corporate/scientific sphere to the heart of the patient community. The Living Beyond Breast Cancer (LBBC) conference celebrated its 20th year, providing a dedicated space for those living with Stage IV disease—a group often overlooked in traditional "pink ribbon" awareness campaigns that focus heavily on early detection and "cures."
During this conference, the METAvivor team maintained a constant presence. While board member Tim Bigelow managed the organization’s booth, the rest of the leadership participated in sessions that ranged from high-level genomic research to the psychological toll of terminal illness.
Phase III: The Emotional Pivot and Personal Milestone
A pivotal moment in the chronology occurred when Dr. Shanahan stepped outside her traditional "scientific" persona to join a panel entitled “The emotional impact of living long-term with MBC.” For a trained physician who prioritizes evidence-based data, this transition into the emotional nuances of the disease represented a significant personal and professional evolution.
Simultaneously, the arrival of Dr. Shanahan’s latest scan results provided a triumphant bookend to the month’s advocacy. The confirmation that her clinical trial drugs are effectively suppressing the disease serves as a powerful testament to the very research METAvivor works to fund.
Supporting Data: The Reality of Metastatic Breast Cancer
To understand the significance of METAvivor’s work, one must look at the data surrounding metastatic breast cancer. MBC, also known as Stage IV, occurs when cancer spreads beyond the breast to vital organs such as the bones, liver, lungs, or brain.
The Funding Disparity
Historically, breast cancer advocacy has focused on "awareness" and "early detection." However, statistics show that nearly 30% of women diagnosed with early-stage breast cancer will eventually see their disease progress to the metastatic stage, regardless of their initial treatment or lifestyle.
Despite this, only an estimated 2% to 5% of all breast cancer research funding is dedicated to the metastatic stage—the stage that is responsible for virtually all breast cancer deaths. METAvivor was founded to address this specific gap, directing 100% of its net donations toward research grants for Stage IV cancer.
The Rise of the "Patient-Scientist"
The presence of eight board members at the LBBC conference reflects the "patient-scientist" model. Dr. Shanahan’s own transition from an OB/GYN to a patient-advocate illustrates a unique dual perspective. The data suggests that when patients are involved in grant reviews—as METAvivor encourages—the research funded is more likely to focus on quality of life and extending survival rather than just theoretical biology.
Clinical Trial Efficacy
Dr. Shanahan’s positive response to her clinical trial is part of a growing body of data suggesting that "precision medicine" is changing the prognosis for MBC. While MBC remains incurable, the goal of modern oncology is to turn it into a chronic, manageable disease. Dr. Shanahan’s report of decreased activity in "every one of [her] many metastases" after 60 days is a statistically significant outcome that underscores the importance of patient participation in trials.
Official Responses: Recognition of the "Changemakers"
The designation of Dr. Kelly Shanahan and Janice Cowden as "Changemakers" by Living Beyond Breast Cancer (LBBC) is an official acknowledgement of their impact on national policy and patient support.
In a statement regarding the honor, LBBC highlighted that with metastatic breast cancer, "every moment counts." The award recognizes those who have moved beyond their own diagnosis to dismantle the stigma surrounding Stage IV disease.
Janice Cowden, a fellow METAvivor board member, has been instrumental in peer-to-peer support training. Her work focuses on the "Peer-to-Peer" leadership program, which METAvivor promoted heavily during the Philadelphia conference. This program trains volunteers to lead support groups in their local areas, ensuring that no patient has to navigate a terminal diagnosis in isolation.
Crystal Moore, Executive Director of METAvivor, emphasized the importance of the in-person gathering in Philadelphia. She noted that the synergy of having board members from California to New Jersey in one room accelerates the decision-making process for upcoming grant cycles and advocacy initiatives.
Implications: The Future of MBC Advocacy
The events of the past month signal a maturing of the MBC advocacy movement. There are several long-term implications for the medical community and the patient population.
1. From Awareness to Action
The "pink ribbon" era of breast cancer awareness is being supplemented by a more rigorous, "action-oriented" approach. METAvivor’s focus on grant reviews and clinical trial advocacy suggests that the community is no longer satisfied with "awareness" alone; they are demanding a seat at the table where research dollars are allocated.
2. The Integration of Mental Health and Science
Dr. Shanahan’s participation in the panel on emotional impact suggests a growing recognition that "living long-term" with a terminal diagnosis requires a specialized psychological framework. As treatments improve and patients live longer with MBC, the healthcare system must adapt to provide long-term mental health support that addresses the unique "scanxiety" and grief associated with the disease.
3. The Power of Clinical Trial Literacy
Dr. Shanahan’s "clinical trial saga" serves as a public case study. By sharing her journey—both the setbacks and the successes—she is demystifying the trial process. This is likely to increase trial enrollment, which is currently a bottleneck in the development of new cancer therapies.
4. Expansion of Peer-Led Support
The surge in interest for METAvivor’s "Take Action" initiatives, specifically in grant reviewing and peer leadership, indicates a highly motivated patient population. This decentralized model of support ensures that advocacy remains grassroots while maintaining a national impact.
Conclusion
As Dr. Shanahan returned from her travels "exhausted and energized," the sentiment reflects the current state of the MBC community. The path forward is grueling, defined by the constant loss of peers and the physical toll of treatment. However, the energy derived from scientific progress and community solidarity is palpable.
Through the leadership of METAvivor and the courage of "Changemakers" like Shanahan and Cowden, the narrative of metastatic breast cancer is being rewritten—from a story of a silent end to a loud, persistent, and evidence-based fight for more time.
For more information on how to get involved or to support metastatic breast cancer research, visit the METAvivor Take Action page.
About the Author
